adjuvant

News

BMS claims first EU okay for adjuvant oesophageal cancer imm...

Bristol-Myers Squibb is in a battle with Merck & Co for position in the upper gastrointestinal cancer immunotherapy market, and has just reinforced its position with an EU approval in t

News

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

AstraZeneca and Merck & Co's Lynparza is primed for even wider use in the treatment of breast cancer after a phase 3 trial showed it could extend the time for the cancer to return when

News

Filing beckons as Lynparza hits the mark in adjuvant breast ...

AstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, according to the data monitoring body for the phase 3 OlympiA trial.

News

"Tokyo, Japan - May 11, 2012: Pfizer building on May 11, 2012 in Tokyo. Pfizer is one of largest pharmaceutical companies worldwide with tremendous revenue $67.4 bn USD for 2011. It exists since 1849."

Ibrance trial failure dashes Pfizer’s growth hopes for the d...

Pfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set back its hopes of even loftier sales – and set up a challenge from Eli Lilly’s

News

GSK to produce a billion doses of COVID-19 vaccine booster b...

GlaxoSmithKline is to scale up production of its COVID-19 vaccine booster to a billion doses by 2021 to support development of several potential jabs.

BMS claims first EU okay for adjuvant oesophageal cancer imm...

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

Filing beckons as Lynparza hits the mark in adjuvant breast ...

Ibrance trial failure dashes Pfizer’s growth hopes for the d...

GSK to produce a billion doses of COVID-19 vaccine booster b...

Setback for MSD as German court blocks Keytruda SC launch

How to meet your physicians where they are online

adjuvant

Editor's Picks